Skip to main content
logo
Immutep Limited (ASX:IMM)
Australia flag Australia · Delayed Price · Currency is AUD
0.0220
-0.0020 (-8.33%)
Oct 22, 2026, 4:10 PM AEDT

Immutep Revenue

In the fiscal year ending June 30, 2026, Immutep had annual revenue of 14.60M AUD with 24,344.44% growth. Immutep had revenue of 10.50M in the half year ending June 30, 2026, with 34,682.21% growth. That makes Immutep the 35,733rd largest company in the world by revenue and 623rd in Australia.

Revenue
14.60M
Revenue Growth
+24,344.44%
P/S Ratio
1.63
Revenue / Employee
643.04K
Employees
31
Market Cap
32.42M

Revenue Chart

Chart

Revenue by Segment

Chart
  • Immunotherapy 5.03M 99.8%
  • Unallocated 9.24K 0.2%
Fiscal year ended Jun 30, 2025 See the full Immutep breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Jun 30, 202614.60M14.54M24,344.44%
Jun 30, 202559.71K-59.38K-49.86%
Jun 30, 2024119.09K-72.63K-37.88%
Jun 30, 2023191.72K-62.67K-24.63%
Jun 30, 2022254.39K-58.45K-18.68%
Jun 30, 2021312.84K-7.45M-95.97%
Jun 30, 20207.77M6.47M499.78%
Jun 30, 20191.29M-2.34M-64.42%
Jun 30, 20183.64M2.84M354.63%
Jun 30, 2017800.46K625.41K357.27%
Jun 30, 2016175.05K--
Jun 30, 2015---
Jun 30, 2014---
Jun 30, 2013---
Jun 30, 2012---
Jun 30, 2011---
Jun 30, 2010---
Jun 30, 2009---
Jun 30, 2008---
Jun 30, 2007---
Jun 30, 2006---
Jun 30, 2005---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Botanix Pharmaceuticals33.80M
Neurizon Therapeutics17.59M
Radiopharm Theranostics12.87M
Amplia Therapeutics4.79M
Neurotech International4.73M
Alterity Therapeutics3.61M
Arovella Therapeutics3.50M
Entropy Neurodynamics1.91M
Revenue Rankings

Immutep News

More News